BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Atacand candesartan cilexetil: Phase III data

The double-blind, European Phase III SCAST trial in 2,029 patients with acute stroke and a systolic blood pressure >=140 mmHg showed that Atacand missed the co-primary endpoints of significantly reducing a composite of vascular death, MI or stroke (120 vs. 111 events, p=0.52) and of significantly reducing the...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >